FGFR1 and breast carcinoma: In addition, FGFR1 amplification was associated with distant metastasis, early relapse and poor survival [3, 9–11], and contributed to poor prognosis in luminal breast cancers by driving anchorage independent proliferation and endocrine therapy resistance [10].